VolitionRX Limited Common Stock (VNRX)

FairStock Score: 23/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for proven economics, durable competitive advantages, and a price that offers a margin of safety. VolitionRx has none of those yet. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $398,657 and net loss was $7.3 million. In fiscal Q1 2026, revenue was $985,076 and net loss was $6.7 million. For FY2025, the period ended 2025-12-31, revenue was $1.7 million and net loss was $23.4 million. Those are not the numbers of a self-sustaining enterprise. The company is trying to commercialize epigenetics blood tests, but with 57 employees and a market value of $2.5 million at the 2026-10-13 close, the market is not paying for much success. FairStock's price-to-earnings is -0.05, return on capital employed is -142.94%, free cash flow is negative $19.6 million, and its FCF yield is -797.1%. Its Piotroski score is 1/9, Altman Z-score is -48.04, and overall FairStock score is 23/100. Revenue has grown from $775,302 in FY2023 to $1.2 million in FY2024 to $1.7 million in FY2025, but losses remain enormous and cash is being consumed. The Lynch category is none, because the company lost money in each of the last four years. The 52-week range of $0.15 to $3.26 shows how violent sentiment can be. A diagnostic idea can have option value, but on reported figures I cannot identify a moat or a bargain. Without a credible path to positive cash flow, this is a speculation on financing and future adoption, not a Graham-style value investment.

In plain English: VolitionRx is a small healthcare company that develops blood tests for cancers and other diseases in people and animals. The business looks weak today: sales are tiny and it loses millions of dollars each quarter. At 18 cents a share, the price does not look cheap compared with those small sales and large losses.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer